Biologically Active Small Molecules

A selective inhibitor of FGFR4 (IC₅₀s = 3, 591, 493, and 150 nM for FGFR4, 1, 2, and 3, respectively) inhibits proliferation of HCC cells (EC₅₀s = 0.02-0.

A selective CSF1R inhibitor (IC₅₀ = 1 nM) that inhibits CSF1-dependent proliferation (EC₅₀ = 67 nM in bone marrow-derived macrophages) blocks tumor progression and significantly improves survival in glioma-bearing mice as well

A selective CSF1R inhibitor (IC₅₀ = 1 nM) that inhibits CSF1-dependent proliferation (EC₅₀ = 67 nM in bone marrow-derived macrophages) blocks tumor progression and significantly improves survival in glioma-bearing mice as well

A selective CSF1R inhibitor (IC₅₀ = 1 nM) that inhibits CSF1-dependent proliferation (EC₅₀ = 67 nM in bone marrow-derived macrophages) blocks tumor progression and significantly improves survival in glioma-bearing mice as well

A selective CSF1R inhibitor (IC₅₀ = 1 nM) that inhibits CSF1-dependent proliferation (EC₅₀ = 67 nM in bone marrow-derived macrophages) blocks tumor progression and significantly improves survival in glioma-bearing mice as well

A dual acting antithrombogenic agent inhibitor of TXA2 synthase (IC50 = 12 nM) acts as an TP receptor antagonist (IC50 = 1.1 nM).

A dual acting antithrombogenic agent inhibitor of TXA2 synthase (IC50 = 12 nM) acts as an TP receptor antagonist (IC50 = 1.1 nM).

A dual acting antithrombogenic agent inhibitor of TXA2 synthase (IC50 = 12 nM) acts as an TP receptor antagonist (IC50 = 1.1 nM).

An orally available PARP1 and PARP2 inhibitor (Kis = 1.2 and 0.85 nM, respectively) selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors.

An orally available PARP1 and PARP2 inhibitor (Kis = 1.2 and 0.85 nM, respectively) selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors.

An orally available PARP1 and PARP2 inhibitor (Kis = 1.2 and 0.85 nM, respectively) selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors.

An orally available PARP1 and PARP2 inhibitor (Kis = 1.2 and 0.85 nM, respectively) selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene mutations and elicits antitumor activity in xenografted tumors.